Pre-treatment circulating reproductive hormones levels predict pathological and survival outcomes in breast cancer submitted to neoadjuvant chemotherapy.
Ailin LanYudi JinYu WangYihua WangNan DingYuran DaiLinshan JiangZhenrong TangYang PengShengchun LiuPublished in: International journal of clinical oncology (2022)
Pre-treatment testosterone and FSH are significant independent predictors for pCR to NAC in premenopausal and postmenopausal patients, respectively. Low progesterone levels are correlated with worse OS in premenopausal patients. These findings may provide a theoretical basis for pre-operative endocrine therapy combined with NAC in breast cancer.
Keyphrases
- neoadjuvant chemotherapy
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- transcription factor
- prognostic factors
- peritoneal dialysis
- postmenopausal women
- squamous cell carcinoma
- stem cells
- radiation therapy
- mesenchymal stem cells
- bone mineral density
- patient reported outcomes
- breast cancer risk
- young adults
- locally advanced
- bone marrow
- sentinel lymph node
- genome wide analysis